-
There are 13 PD-(L)1 models in China, and the competition is fierce. What can the late entrants rely on?
Time of Update: 2022-04-28
HK) announced that its first self-developed innovative biopharmaceutical PD-1 inhibitor H drug-Hanszoid® (generic name: slulimumab injection) Liquid) was officially approved by the State Food and Drug Administration for the indication of adult advanced solid tumors with unresectable or metastatic microsatellite instability-high (MSI-H) who have failed previous standard therapy .
-
by the FDA, and 4 PD-1 models have been listed in the United States in China
Time of Update: 2021-09-19
It is reported that BeiGene's listing application is based on the results of a randomized, open, multi-center global phase 3 clinical trial RATIONALE 302 (NCT03430843), which aims to evaluate the comparative study of tislelizumab injection The effectiveness and safety of the chemotherapy selected by the patient for the second-line treatment of patients with advanced or metastatic ESCC .
-
Negotiations are not the only way 3 PD-1 models enter Foshan's commercial supplementary medical insurance
Time of Update: 2019-12-24
On December 23, Foshan Medical Insurance Bureau issued the announcement of "Foshan social insurance fund administration on the implementation of Foshan commercial supplementary medical insurance" Ping
-
Negotiations are not the only way 3 PD-1 models enter Foshan's commercial supplementary medical insurance
Time of Update: 2019-12-23
Author: On December 23, Foshan Medical Insurance Bureau issued the announcement of "Foshan social insurance fund administration on the implementation of Foshan commercial supplementary medical insuran
-
The Chinese Academy of Environmental Sciences expands the "1+X" joint research model
Time of Update: 2023-02-10
" Xu Qigong, executive deputy director of the Collaboration Center and vice president of the Academy of Environmental Sciences, said that the Collaboration Center will jointly The advantages of resources in related fields inside and outside the Academy of Sciences, systematically build a scientific research innovation platform of "multi-discipline, multi-field participation, and multi-media integration" .
-
Preprint: Models predict that the coronavirus outbreak in China could cause 1 million deaths
Time of Update: 2022-12-30
"However, two studies have found that deaths could be reduced by giving most people a fourth dose of the vaccine, as well as high adherence to mask wearing and re-imposing temporary restrictions on social interactions when mortality soars.
-
The "Sea-based No. 1" deep-sea heavy vehicle was put into operation to open up a new model for the development of deep-water oil and gas resources in China
Time of Update: 2022-10-18
On October 3, the first deepwater duct frame platform in Asia, "Haiji No. 1", independently designed and built by CNOOC, was put into use, marking China's successful opening up of a new model for oil
-
Effect of peripheral CB 1 receptor antagonist JD5037 in the use of the AMPK-activated agent
Time of Update: 2022-10-02
To find new targets and therapeutic strategies that do not involve pulmonary vasodilation, we investigated the effects of the peripheral CB 1 receptor antagonist JD5037 and the AMPK activator metformin on MCT-induced PH in rats, respectively and in combination.
-
The team of Professor Gao Feng and Professor Xianghui Yu isolated anti-HIV-1 broad-spectrum
Time of Update: 2022-04-26
The research team of Professor Gao Feng and Professor Yu Xianghui from the School of Life Sciences of Jilin University took the rhesus monkey animal model with the longest reported infection time as t
-
Arthritis: Interleukin 1 receptor-related kinase 4 inhibitor PF-06650833 blocks a preclinical model of rheumatism
Time of Update: 2022-04-17
In the current study, we demonstrate that PF-06650833, a small-molecule inhibitor of IRAK4, reduces responses to disease-related stimuli in human cells as well as in animal models of rheumatoid arthritis and systemic lupus erythematosus .
-
Express | Open up a new model of targeted RNA, Janssen reached a cooperation of over 1 billion US dollars
Time of Update: 2022-03-02
On February 17, 2022, Remix Therapeutics announced an R&D collaboration with Janssen, a subsidiary of Johnson & Johnson, to use Remix's REMaster drug discovery platform to develop small molecule therapeutics that modulate RNA processing .
-
The 6th "Models of State-owned Enterprises" released in Beijing, 1 employee and 1 team in the petrochemical industry were selected
Time of Update: 2022-01-08
For 34 years, he has been deeply involved in scientific research, leading the team to break the foreign technology blockade many times, and obtained 32 authorized invention patents, all of which realized industrial applications, allowing China's lubrication technology to achieve a leap from introduction to independent research and development .
-
Cancers (Basel): Using machine learning models to study the related factors of thyroid-related
Time of Update: 2021-12-04
This study used a variety of machine learning models to predict and found that factors such as smoking history, hypertension, and opioids were associated with thyroid-related adverse events in cancer patients receiving PD-1/PD-L1 inhibitors .
-
2021 CSCO Professor Qing Xu: A new model for the treatment of malignant mesothelioma-αPD-1-mesoCAR-T cell therapy
Time of Update: 2021-11-04
mesoCAR-T cell therapy Professor Qing Xu: At present, immunotherapy represented by PD-1 antibody is in the center of tumor treatment, but there are still some tumors, including malignant pleural stromal tumors, with relatively low benefit rates.
-
Express genetically engineered probiotics to provide a new treatment model for type 1 diabetes
Time of Update: 2021-10-22
▎The content team editor of WuXi AppTec recently, Precigen ActoBio announced the positive interim data of the phase 1b/2a clinical trial of the microbial therapy AG019 under investigation for the treatment of type 1 diabetes (T1D) .